☆
Watchlist
Log in
Sign-up
Fisher & Paykel Healthcare Corporation Ltd (fph) Logo

Fisher & Paykel Healthcare Corporation Ltd (FPH)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE
Overview
Financials (10-yr)

FPH Chart

Snapshot

FPH's Principal Activity is the the company is a designer, manufacturer and marketer of�products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -27.68%
vs ASX 200 (1yr) -28.14%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 40 of 2,420
Sector Rank 6 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies RMD / COH / EBO
EPS $0.65
DPS $0.3829
Book Value Per Share $2.70

Broker Consensus

Breakdown 7 Buy · 2 Hold · 3 Sell
Recommendation Buy
Last Updated 04/06/22

Top Market Index News

More News

Announcements

Date Heading Pages File Size Time

Corporate Overview

Fisher & Paykel Healthcare Corporation Limited (FPH) is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company's products are sold in over 120 countries worldwide.

Incorporation Details

Incorporated Following the separation of Fisher & Paykel Industries Limited into two companies: Fisher & Paykel Healthcare Corporation Limited (FPH) and Fisher & Paykel Appliances Holdings Limited (FPA), listed on ASX on 21 Novemeber 2001.

Corporate Details

Head Office East Tamaki New Zealand 2013
Website www.fphcare.com
Registry Link Market Services
Auditor PWC
Date Listed 21 Nov 2001

Upcoming Calendar (Forecasted)

Date Event
06/07/2022 Div Pay Date
24/08/2022 AGM
24/11/2022 Report (Interim)
24/05/2023 Report (Prelim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
22/06/2022 $0.2046 0% $0.2046 Final 06/07/2022
02/12/2021 $0.1784 0% $0.1784 Interim 15/12/2021
24/06/2021 $0.2046 0% $0.2046 Final 07/07/2021
03/12/2020 $0.151 0% $0.151 Interim 16/12/2020
06/07/2020 $0.1463 0% $0.1463 Final 17/07/2020
06/12/2019 $0.1148 0% $0.1148 Interim 19/12/2019
13/06/2019 $0.1287 0% $0.1287 Final 05/07/2019
07/12/2018 $0.0921 0% $0.0921 Interim 21/12/2018
21/06/2018 $0.1151 0% $0.1151 Final 06/07/2018
05/12/2017 $0.0803 0% $0.0803 Interim 20/12/2017
15/06/2017 $0.1074 0% $0.1074 Final 07/07/2017
06/12/2016 $0.0789 0% $0.0789 Interim 21/12/2016
16/06/2016 $0.0955 0% $0.0955 Final 08/07/2016
09/12/2015 $0.0629 0% $0.0629 Interim 23/12/2015
17/06/2015 $0.071 0% $0.071 Final 10/07/2015
03/12/2014 $0.0537 0% $0.0537 Interim 19/12/2014
18/06/2014 $0.065 0% $0.065 Final 04/07/2014
02/12/2013 $0.0491 0% $0.0491 Interim 19/12/2013
17/06/2013 $0.0586 0% $0.0586 Final 05/07/2013
27/11/2012 $0.0426 0% $0.0426 Interim 14/12/2012
18/06/2012 $0.055 0% $0.055 Final 06/07/2012
28/11/2011 $0.0413 0% $0.0413 Interim 16/12/2011
20/06/2011 $0.0534 0% $0.0534 Final 08/07/2011
29/11/2010 $0.0418 0% $0.0418 Interim 17/12/2010
21/06/2010 $0.0578 0% $0.0578 Final 09/07/2010
03/12/2009 $0.0429 0% $0.0429 Interim 18/12/2009
15/06/2009 $0.056 0% $0.056 Final 06/07/2009
Show All

See Upcoming Dividends for all ASX companies.

Key Data
DPS(TTM) $0.3829
Gross DPS(TTM) $0.3829
Dividend yield
Gross yield
Payout Ratio 61%
DRP Yes
DRP Features 3% Discount

Directors & Management

Directors & Management

Name Title Since Bio
Dr Cather Simpson Non-Executive Director Jun 2022

Dr Cather Simpson

Non-Executive Director

Dr Simpson is a professor of physics and chemical sciences at the University of Auckland and a partner at Pacific Channel, an early-stage investment company. She is a director of the International Society for Optics & Photonics (SPIE) and founder/director for Orbis Diagnostics. Dr Simpson also serves on the advisory boards of the Paihau-Robinson Research Institute at Victoria University and the New Zealand Product Accelerator. In 2010, Dr Simpson founded and directed The Photon Factory at the University of Auckland. She is a founder of three high-tech start-up businesses, including Engender Technologies, where she served as Chief Science Officer from 2011 to 2021. She is also a member of the Quality, Safety and Regulatory Committee
Dr Lisa Margaret McIntyre Non-Executive Director Oct 2021

Dr Lisa Margaret McIntyre

Non-Executive Director

Ms McIntyre is a director of HCF Group, The University of Sydney, Studiosity, and Nanosonics. In addition to her current directorships, she has previously been a director of a range of health entities, including those in healthcare insurance, clinical service delivery and medical research and innovation. She spent 20 years as a senior strategy partner with LEK Consulting providing advice to companies in North America, Asia and Australia.
Mr Neville Mitchell Non-Executive Director Nov 2018

Mr Neville Mitchell

Non-Executive Director

Mr Mitchell was Chief Financial Officer and Company Secretary of Cochlear Limited between 1995 and 2017. He is a nonexecutive director of Sonic Healthcare and Q'Biotics Group and a former director of The Board of Tax, South East Sydney Local Health District, Osprey Medical and Sirtex Limited. Previously, he served on the New South Wales Medical Devices Fund, was Chairman of the Group of 100, and Chairman, Standing Committee (Accounting and Auditing), for the Australian Securities and Investments Commission.
Ms Philippa (Pip) Mary Greenwood Non-Executive Director Jun 2017

Ms Philippa (Pip) Mary Greenwood

Non-Executive Director

Mr Greenwood is chair of Westpac New Zealand Limited, a director of a2 Milk Company Limited and Vulcan Steel Limited, a current trustee of the Auckland Writers Festival and served as a member of the New Zealand Takeovers Panel from 2007 to 2011. Mr Greenwood was a partner at Russell McVeagh between 2001 and 2019 and served as the firm's Board Chair. She has advised on many high-profile corporate transactions. He is chair of People committee.
Mr Lewis George Gradon Chief Executive Officer,Managing Director Apr 2016

Mr Lewis George Gradon

Chief Executive Officer,Managing Director

Mr Gradon became Managing Director & Chief Executive Officer in April 2016. Prior to that, he spent 15 years as Senior Vice President - Products & Technology, and six years as General Manager - Research and Development. During his 38-year tenure with Fisher & Paykel Healthcare he has held various engineering positions overseeing the development of our range of products as well the development of our manufacturing, quality, intellectual property, supply chain and clinical research functions.
Mr Scott Andrew St John Non-Executive Director,Non-Executive Chairman Oct 2015

Mr Scott Andrew St John

Non-Executive Director,Non-Executive Chairman

Mr John is director of ANZ New Zealand Bank Limited, Mercury Limited, the NEXT Foundation and Fonterra Cooperative Group Limited. Scott was Chief Executive Officer of First NZ Capital from 2002 to 2017. He previously served as the Chancellor of the University of Auckland, Chairman of the Securities Industries Association and was a member of the Financial Markets Authority Establishment Board. He is member of risk and people and r Quality, Safety & Regulatory Committee.
Ms Geraldine Celia McBride Non-Executive Director Aug 2013

Ms Geraldine Celia McBride

Non-Executive Director

Ms McBride has been involved in the technology industry for 30 years and has a wealth of global experience. She has held senior executive roles at SAP AG and Dell Inc, and is a former President of SAP North America. She is a director of Sky Network Television Ltd and the founder and CEO of MyWave.
Mr Donal Paul O'Dwyer Non-Executive Director Dec 2012

Mr Donal Paul O'Dwyer

Non-Executive Director

Mr O'Dwyer is a director of nib Holdings Limited. From 1996 to 2003, he was with Cordis Cardiology (a division of Johnson & Johnson), initially as its president (Europe) and from 2000 to 2003 as its worldwide president. Prior to joining Cordis, he worked for 12 years with Baxter Healthcare, rising from plant manager in Ireland to president of the Cardiovascular Group, Europe, now Edwards Lifesciences. Previously he served on the boards of Cochlear Limited, Cordis Asset Management and Mesoblast Limited.
Mr Michael Grenfell Daniell Non-Executive Director Nov 2001

Mr Michael Grenfell Daniell

Non-Executive Director

Mr Daniell was Managing Director and Chief Executive Officer of Fisher & Paykel Healthcare from November 2001 to March 2016. He was General Manager of Fisher & Paykel's medical division from 1990 to 2001 and previously held various technical management and product design roles within the company. Mr Daniell is a director of Cochlear Limited, Tait Limited, the Medical Research Commercialisation Fund, and Chair of Te Titoki Mataora - MedTech Research Translator. He was named a Knight Companion of the New Zealand Order of Merit in June 2021. He is member of risk committee.
Mr Marcus James Driller Company Secretary,Vice President - Corporate N/A
Lyndal York Chief Financial Officer N/A
Paul Shearer Senior Vice President - Sales & Marketing N/A
Marcus Driller Vice President - Corporate N/A
Nicola Talbot Vice President - Human Resources N/A
Nicholas Fourie Vice President - Information & Communication Technology N/A
Andrew Somervell Vice President - Products & Technology N/A
Brian Schultz Vice President - Quality & Regulatory Affairs N/A
Jonti Rhodes Vice President - Supply Chain, Facilities & Sustainability N/A
Winston Fong Vice President - Surgical Technologies N/A

Director Transactions

FPH directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
01/06/22 Scott St John Buy +500 $20.92 $10,460 As advised by the company
06/12/21 Lisa McIntyre Buy +4,400 $32.452 $142,790 As advised by the company
16/09/21 Lewis Gradon Sell +80,000 $31.215 ($2,497,192) As advised by the company
16/09/21 Lewis Gradon Buy +32,466 $30.54 $991,511 Conversion of securities
16/09/21 Lewis Gradon Exercise 32,466 $30.54 $991,511 Conversion of securities
16/09/21 Lewis Gradon Buy +53,038 $30.54 $1,619,780 Exercise of options
16/09/21 Lewis Gradon Exercise 100,313 $30.54 $3,063,559 Exercise of options
01/09/21 Lewis Gradon Issued 25,761 $31.57 $813,274 Issue of securities
01/09/21 Lewis Gradon Issued 73,633 $31.57 $2,324,593 Issue of options
04/03/21 Scott St John Buy +500 $28.05 $14,025 As advised by the company
27/11/20 Scott St John Buy +1,500 $32.47 $48,705 As advised by the company
10/09/20 Lewis Gradon Exercise 64,598 $30.85 $1,992,848 Conversion of securities
10/09/20 Lewis Gradon Issued 22,178 $30.85 $684,191 Issue of securities
10/09/20 Lewis Gradon Sell +135,000 $33.822 ($4,565,936) As advised by the company
10/09/20 Lewis Gradon Issued 64,598 $30.85 $1,992,848 Conversion of securities
08/09/20 Lewis Gradon Issued 73,529 $31.27 $2,299,251 Issue of securities
08/09/20 Lewis Gradon Cancelled 111,364 $31.27 $3,482,352 Cancellation of securities
08/09/20 Lewis Gradon Issued 69,931 $31.27 $2,186,742 Issue of options
02/07/20 Michael Daniell Cancelled 20,000 $32.40 $648,000 Cancellation of securities
02/07/20 Michael Daniell Issued 15,901 $35.281 $561,004 Issue of securities
02/07/20 Lewis Gradon Sell +136,000 $34.307 ($4,665,765) As advised by the company
02/07/20 Lewis Gradon Issued 86,147 $0.035 $3,039 Issue of securities
02/07/20 Lewis Gradon Cancelled 115,000 $32.40 $3,726,000 Cancellation of securities
01/07/20 Scott St John Buy +1,500 $34.887 $52,330 As advised by the company
01/07/20 Michael Daniell Sell +90,000 $34.269 ($3,084,209) As advised by the company
03/12/19 Michael Daniell Issued 13,458 $21.30 $286,655 Issue of securities
03/12/19 Michael Daniell Cancelled 20,000 $20.24 $404,800 Cancellation of securities
03/12/19 Scott St John Buy +1,000 $21.20 $21,200 As advised by the company
02/12/19 Michael Daniell Sell +11,000 $22.004 ($242,040) As advised by the company
11/09/19 Lewis Gradon Issued 43,848 $15.84 $694,552 Issue of securities
11/09/19 Lewis Gradon Issued 138,827 $15.84 $2,199,020 Issue of options
26/06/19 Scott St John Buy +1,500 $15.26 $22,890 As advised by the company
Show All

Director Interests

The current holdings of FPH directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Scott St John 01/06/2022 21,500 N/A N/A N/A
Lisa McIntyre 06/12/2021 N/A 4,400 N/A N/A
Lewis Gradon 16/09/2021 518,159 642,280 282,391 N/A
Philippa (Pip) Greenwood 31/03/2021 N/A 3,800 N/A N/A
Geraldine McBride 31/03/2021 1,262 N/A N/A N/A
Donal O'Dwyer 31/03/2021 N/A 68,569 N/A N/A
Neville Mitchell 31/03/2021 7,200 N/A N/A N/A
Michael Daniell 31/03/2021 N/A 900,168 N/A N/A
Cather Simpson N/A N/A N/A N/A N/A

Shareholder Info

Top 20 Shareholders
About the Data

Data supplied by Morningstar and accurate on Mar 31, 2022.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
HSBC Nominees (New Zealand) Limited 86,829,223 15.04%
HSBC Nominees (New Zealand) Limited I 62,962,474 10.90%
JPMorgan Chase Bank 45,632,917 7.90%
HSBC Custody Nominees (Australia) Limited II 35,903,950 6.22%
Citibank Nominees (NZ) Ltd 35,592,530 6.16%
Citicorp Nominees Pty Limited 30,979,653 5.37%
JPMorgan Nominees Australia Pty Limited 22,113,072 3.83%
Custodial Services Limited 21,711,197 3.76%
BNP Paribas Nominees NZ Limited Bpss40 16,388,355 2.84%
Tea Custodians Limited 15,304,488 2.65%
New Zealand Superannuation Fund Nominees Limited 13,554,912 2.35%
Accident Compensation Corporation 10,290,860 1.78%
National Nominees New Zealand Limited 9,933,255 1.72%
Bnp Paribas Noms Pty Ltd 7,657,125 1.33%
Premier Nominees Limited 7,502,780 1.30%
BNP Paribas Nominees NZ Limited 7,381,347 1.28%
National Nominees Limited 6,681,350 1.16%
FNZ Custodians Limited 6,668,772 1.15%
JBWere (NZ) Nominees Limited 5,124,038 0.89%
New Zealand Depository Nominee 4,958,781 0.86%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 15,814 8,996 1,898 1,116 65 27,889

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
BlackRock, Inc and related bodies corporate 31/03/2022 37,908,016 6.60
Hyperion Asset Management Limited 17/05/2022 28,932,079 5.01
Mitsubishi UFJ Financial Group, Inc 26/05/2022 41,852,730 7.25
Pinnacle Investment Management Group Limited 12/05/2022 29,363,690 5.09

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
26-05-22 Mitsubishi UFJ Financial Group, Inc 6,639,641 6.10 7.25
17-05-22 Hyperion Asset Management Limited 28,932,079 -- 5.01
12-05-22 Pinnacle Investment Management Group Limited 29,363,690 -- 5.09
22-09-21 Mitsubishi UFJ Financial Group, Inc 6,095,588 5.05 6.10

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $28.92 30 June
2020 $32.84 30 June
2019 $14.83 28 June
2018 $13.68 29 June
2017 $10.85 28 June
2016 $9.56 28 June
2015 $6.09 30 June
2014 $4.43 30 June
FPH Historical Price Data (CSV)
Up to 20 years of EOD share price history
Sign up to Download
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.